These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38060051)

  • 1. Longitudinal evaluation of health-related quality of life after removal of high-risk melanoma in a setting where adjuvant therapy is not available.
    Sladojevic J; Dotlic J; Gazibara T; Matkovic S; Maksimovic N
    Arch Dermatol Res; 2023 Dec; 316(1):27. PubMed ID: 38060051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
    Bottomley A; Coens C; Mierzynska J; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Puig S; Ascierto PA; Larkin J; Lorigan PC; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C; Eggermont AMM;
    Lancet Oncol; 2021 May; 22(5):655-664. PubMed ID: 33857414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Quality of Life With Surgical Excision of Early-Stage Melanoma of the Head and Neck.
    Mori S; Blank NR; Connolly KL; Dusza SW; Nehal KS; Rossi AM; Lee EH
    JAMA Dermatol; 2019 Jan; 155(1):85-89. PubMed ID: 30422228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion.
    Bagge AS; Ben-Shabat I; Belgrano V; Olofsson Bagge R
    Ann Surg Oncol; 2016 Jun; 23(6):2062-9. PubMed ID: 26868956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in patients with fully resected BRAF
    Schadendorf D; Di Giacomo AM; Demidov L; Merelli B; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Hong A; Lewis K;
    Eur J Cancer; 2019 Dec; 123():155-161. PubMed ID: 31704549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
    Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
    Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema.
    Gjorup CA; Groenvold M; Hendel HW; Dahlstroem K; Drzewiecki KT; Klausen TW; Hölmich LR
    Eur J Cancer; 2017 Nov; 85():122-132. PubMed ID: 28918186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
    Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J;
    Acta Oncol; 2013 Aug; 52(6):1086-93. PubMed ID: 23621752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy.
    Pedersen S; Holmstroem RB; von Heymann A; Tolstrup LK; Madsen K; Petersen MA; Haslund CA; Ruhlmann CH; Schmidt H; Johansen C; Svane IM; Ellebaek E
    Acta Oncol; 2023 Jan; 62(1):62-69. PubMed ID: 36645166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life of patients with multidrug-resistant tuberculosis in Yemen: prospective study.
    Jaber AAS; Ibrahim B
    Health Qual Life Outcomes; 2019 Aug; 17(1):142. PubMed ID: 31420045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depressive symptoms decrease health-related quality of life of patients with coronary artery disease and diabetes: a 12-month follow up study in primary care.
    Tusa N; Kautiainen H; Elfving P; Sinikallio S; Mäntyselkä P
    Scand J Prim Health Care; 2023 Sep; 41(3):276-286. PubMed ID: 37455531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model.
    Vale L; Kunonga P; Coughlan D; Kontogiannis V; Astin M; Beyer F; Richmond C; Wilson D; Bajwa D; Javanbakht M; Bryant A; Akor W; Craig D; Lovat P; Labus M; Nasr B; Cunliffe T; Hinde H; Shawgi M; Saleh D; Royle P; Steward P; Lucas R; Ellis R
    Health Technol Assess; 2021 Nov; 25(64):1-178. PubMed ID: 34792018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review examining factors influencing health related quality of life among melanoma cancer survivors.
    Hamel JF; Pe M; Coens C; Martinelli F; Eggermont AM; Brandberg Y; Bottomley A
    Eur J Cancer; 2016 Dec; 69():189-198. PubMed ID: 27838512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
    Schadendorf D; Dummer R; Hauschild A; Robert C; Hamid O; Daud A; van den Eertwegh A; Cranmer L; O'Day S; Puzanov I; Schachter J; Blank C; Salama A; Loquai C; Mehnert JM; Hille D; Ebbinghaus S; Kang SP; Zhou W; Ribas A
    Eur J Cancer; 2016 Nov; 67():46-54. PubMed ID: 27596353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery, Limb Edema and Health-related Quality of Life: A Prospective Follow-up Study on Patients With Cutaneous Malignant Melanoma.
    Heino P; Mylläri P; Jahkola T; Luoma ML; Räsänen P; Roine RP
    Anticancer Res; 2022 Nov; 42(11):5507-5519. PubMed ID: 36288873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma.
    Dieng M; Kasparian NA; Cust AE; Costa DSJ; Tran A; Butow PN; Menzies SW; Mann GJ; Morton RL
    JAMA Dermatol; 2018 Jan; 154(1):52-59. PubMed ID: 29188268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.